Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulse diagnosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    797 result(s) found for: Pulse diagnosis. Displaying page 1 of 40.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023495-11 Sponsor Protocol Number: 2010-023495-11 Start Date*: 2010-12-17
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Esmolol to treat tachicardia in septic shock
    Medical condition: septic shock
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043071 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001785-14 Sponsor Protocol Number: STRESS-L Start Date*: 2017-11-09
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)
    Medical condition: Tachycardia in Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10007541 - Cardiac disorders 10043071 Tachycardia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-014276-22 Sponsor Protocol Number: 06FB/DE02 Start Date*: 2010-02-19
    Sponsor Name:Laboratoires Genevrier
    Full Title: Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabeti...
    Medical condition: Diabetic neuropathic foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002138-22 Sponsor Protocol Number: LDLL300.401 Start Date*: 2017-09-15
    Sponsor Name:AOP Orphan Pharmaceuticals GmbH
    Full Title: Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in ICUs
    Medical condition: Adult patients in ICU with septic shock who remain tachycardic (HR ≥95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of ≥65 mmHg after a hemodynamic optimization p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10043071 Tachycardia PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) SI (Completed) HU (Completed) LT (Completed) PL (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001319-38 Sponsor Protocol Number: MW051 Start Date*: 2015-09-24
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Monocenter prospective open single-arm phase IV study of the effects of hawthorn extract WS® 1442 on arterial micro-vascular structure and macro-vascular function, persistance and erectile functio...
    Medical condition: Underlying cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002899-14 Sponsor Protocol Number: CLCZ696A2216 Start Date*: 2012-11-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood press...
    Medical condition: elderly Hypertensive patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006795-16 Sponsor Protocol Number: 2021-3336 Start Date*: 2022-11-18
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study- PULSE
    Medical condition: Maintenance treatment in metastatic non-squamous lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001416-20 Sponsor Protocol Number: DSC/07/2357/29 Start Date*: 2009-05-19
    Sponsor Name:ITALFARMACO
    Full Title: Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Patients with Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003018-11 Sponsor Protocol Number: CQGE031E12301 Start Date*: 2021-10-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolesce...
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10008675 Cholinergic urticaria LLT
    23.0 10040785 - Skin and subcutaneous tissue disorders 10012521 Dermographism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) SI (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005594-29 Sponsor Protocol Number: Moli1901-010 Start Date*: 2006-10-31
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003020-31 Sponsor Protocol Number: 24-08-2015version3.0 Start Date*: 2015-09-03
    Sponsor Name:Department of Dermatology, Bispebjerg University Hospital
    Full Title: Pulse-Daylight-Photodynamic Therapy of Actinic Keratoses
    Medical condition: Actinic keratoses
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10041304 Solar keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003615-28 Sponsor Protocol Number: SPD489-209 Start Date*: 2012-12-21
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005470-69 Sponsor Protocol Number: SPON CU 153 Start Date*: 2007-08-16
    Sponsor Name:Cardiff University
    Full Title: A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin therapy on vascular and metabolic risk in young women with polycystic ovary syndrome.
    Medical condition: Polycystic Ovary Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003053-34 Sponsor Protocol Number: CRC2014EMPA Start Date*: 2015-02-24
    Sponsor Name:IPPMed – Institut für Pharmakologie und Präventive Medizin GmbH
    Full Title: Randomized, double-blind, placebo controlled, crossover clinical study to analyse the effect of empagliflozin on microvascular circulation
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005223-90 Sponsor Protocol Number: PULSE-PAH-004 Start Date*: 2016-07-12
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS W...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005392-10 Sponsor Protocol Number: CBGG492A2204 Start Date*: 2009-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of si...
    Medical condition: Acute migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066635 Acute migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000404-40 Sponsor Protocol Number: BAY 12-8039/11229 Start Date*: 2004-09-06
    Sponsor Name:Bayer plc
    Full Title: A double-blind, randomised, placebo controlled study to investigate chronic intermittent “pulse” therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis.
    Medical condition: Chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    10008841
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011776-30 Sponsor Protocol Number: DE-CAN-027 (BLO K027) Start Date*: 2009-09-07
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg plus Hydrochlorothiazide 25 mg in Patients with Severe Hypertension
    Medical condition: Subjects with severe essential hypertension (SBP between 150 mmHg and 200 mmHg AND DBP between 110 mmHg and 120 mmHg) who did not receive any antihypertensive treatment before will be included in t...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005110-22 Sponsor Protocol Number: SNT-I-018 Start Date*: 2017-11-20
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Ltd
    Full Title: Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004344-30 Sponsor Protocol Number: Moli1901-010A Start Date*: 2005-10-31
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease
    Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:46:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA